Compare Cytokinetics Inc (CYTK) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Standard Lithium Ltd — how do they compare? Cytokinetics Inc trades at $76.52 (market cap $10.63B), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: Cytokinetics Inc is far larger — about 17.6× Standard Lithium Ltd's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| CYTK | SLI | |
|---|---|---|
Market Cap | $10.63B | $604.50M |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $5.65 |
52-Week Low | $34.31 | $1.93 |
Enterprise Value | $10.74B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
SLI trades at $2.43, down 3.95% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported negative profitability metrics, including a -16.6% ROE and -$48.40M net income for 2025, but has beaten EPS estimates in two recent quarters. Recent news highlights institutional buying and progress on its South West Arkansas lithium project, supported by a $225M DOE grant.
The outlook hinges on successful project execution and lithium production timeline, with analyst consensus strongly bullish (100% buy ratings). Key risks include persistent negative cash flow from operations and high capital expenditure needs, which could pressure the balance sheet if project delays occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
